地瓜视频APP免费观看下载安装_www免费视频com_AA区一区二区三无码精片_人人澡人人看_japanese熟睡侵犯

        1. <li id="43v4v"></li>

            <li id="43v4v"></li>

            Recombinant Human IGF-BP7重組人胰島素樣生長(zhǎng)因子結(jié)合蛋白7

            更多活動(dòng)更多優(yōu)惠,盡在翌圣商城》

            批量采購(gòu), 請(qǐng)點(diǎn)擊詢價(jià)

            產(chǎn)品說明書

            FAQ

            COA

            已發(fā)表文獻(xiàn)

            IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids.  Currently, there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II.  IGF-BP7 is expressed in a wide range of normal human tissues, and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin.  It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF-induced differentiation of skeletal myoblasts, without affecting IGF-induced proliferation.  Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF-independent mechanism, which causes a delay in the G1 phase of the cell cycle and increased apoptosis. Recombinant Human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.

             

            Product Properties

            Synonyms

            Insulin-like Growth Factor-Binding Protein 7, IBP-7, Mac25, IGF binding protein related protein-1 (IGFBP-rP1)

            Accession

            Q16270

            GeneID

            3490

            Source

            E.coli-derived HumanIGF-BP7 protein,Leu21-Glu282.

            Molecular Weight

            Approximately 26.4 kDa.

            AA Sequence

            SSSDTCGPCE PASCPPLPPL GCLLGETRDA CGCCPMCARG EGEPCGGGGA GRGYCAPGME CVKSRKRRKG KAGAAAGGPG VSGVCVCKSR YPVCGSDGTT YPSGCQLRAA SQRAESRGEK AITQVSKGTC EQGPSIVTPP KDIWNVTGAQ VYLSCEVIGI PTPVLIWNKV KRGHYGVQRT ELLPGDRDNL AIQTRGGPEK HEVTGWVLVS PLSKEDAGEY ECHASNSQGQ ASASAKITVV DALHEIPVKK GEGAEL

            Tag

            None

            Physical Appearance

            Sterile Filtered White lyophilized (freeze-dried) powder.

            Purity

            > 95 % by SDS-PAGE and HPLC analyses.

            Biological Activity

            Testing in Progress.

            Endotoxin

            0.1 EU per 1μg of the protein by the LAL method.

            Formulation

            Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM Tris-HCl, pH 8.6, 150 mM NaCl.

            Reconstitution

            We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

             

            Shipping and Storage

            The products are shipped with ice pack and can be stored at -20℃ to -80℃ for 1 year.

            Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

             

            Cautions

            1. Avoid repeated freeze-thaw cycles.

            2. For your safety and health, please wear lab coats and disposable gloves for operation.

            3. For research use only.

            HB220318

            400-6111-883